Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMP3X6Q)

Drug Name
Dacetuzumab Drug Info
Synonyms SMR000449312; MLS000758226; MLS001424020; CHEMBL1408911; CCG-100789
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Terminated [1]
Non-hodgkin lymphoma 2B33.5 Terminated [1]
Cross-matching ID
TTD Drug ID
DMP3X6Q

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TNF related activation protein (CD40LG) TTIJP3Q CD40L_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
TNF related activation protein (CD40LG) DTT CD40LG 3.573 2.406 3.632 3.733
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diffuse large B-cell lymphoma
ICD Disease Classification 2A81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TNF related activation protein (CD40LG) DTT CD40LG 8.02E-01 -0.13 -0.7
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
2 A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.Leuk Lymphoma.2010 Feb;51(2):228-35.